KRAS and pancreatic neoplasm: Compound (131) is a highly active helicoid KRAS-PDEδ inhibitor that down-regulates the phosphorylation of key proteins Erk and Akt in the downstream pathway of KRAS, and induces the apoptosis of KRAS-mutated pancreatic cancer cell lines.